Trilaciclib
Cosela (trilaciclib) is a small molecule pharmaceutical. Trilaciclib was first approved as Cosela on 2021-02-12. It is known to target cyclin-dependent kinase 4, cyclin-dependent kinase 6, cyclin-dependent kinase 7, cyclin-dependent kinase 9, and cyclin-dependent kinase 2. Cosela's patents are valid until 2034-03-14 (FDA).
| Trade Name | Cosela |
|---|---|
| Common Name | Trilaciclib |
| Indication | |
| Drug Class | Cyclin dependent kinase inhibitors |
